- Home
- GMS vs VRNA Comparison
GMS vs VRNA Comparison
Compare GMS & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMS
- VRNA
- Stock Information
- Founded
- GMS 1971
- VRNA 2005
- Country
- GMS United States
- VRNA United Kingdom
- Employees
- GMS N/A
- VRNA N/A
- Industry
- GMS
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- GMS
- VRNA Health Care
- Exchange
- GMS Nasdaq
- VRNA Nasdaq
- Market Cap
- GMS 3.3B
- VRNA 3.4B
- IPO Year
- GMS 2016
- VRNA 2017
- Fundamental
- Price
- GMS $84.33
- VRNA $51.89
- Analyst Decision
- GMS Hold
- VRNA Strong Buy
- Analyst Count
- GMS 7
- VRNA 7
- Target Price
- GMS $93.57
- VRNA $50.57
- AVG Volume (30 Days)
- GMS 520.9K
- VRNA 1.4M
- Earning Date
- GMS 02-27-2025
- VRNA 02-27-2025
- Dividend Yield
- GMS N/A
- VRNA N/A
- EPS Growth
- GMS N/A
- VRNA N/A
- EPS
- GMS 5.45
- VRNA N/A
- Revenue
- GMS $5,590,609,000.00
- VRNA $5,624,000.00
- Revenue This Year
- GMS $3.58
- VRNA N/A
- Revenue Next Year
- GMS $2.72
- VRNA $550.30
- P/E Ratio
- GMS $15.48
- VRNA N/A
- Revenue Growth
- GMS 4.12
- VRNA 1127.95
- 52 Week Low
- GMS $77.29
- VRNA $11.39
- 52 Week High
- GMS $105.54
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- GMS 43.37
- VRNA 64.25
- Support Level
- GMS $82.08
- VRNA $43.44
- Resistance Level
- GMS $84.47
- VRNA $55.42
- Average True Range (ATR)
- GMS 1.87
- VRNA 3.32
- MACD
- GMS 0.46
- VRNA 0.40
- Stochastic Oscillator
- GMS 67.95
- VRNA 70.52
About GMS GMS Inc.
GMS Inc is a distributor of specialty building products including wallboard, suspended ceiling systems, ceilings, steel framing, and other complementary building products. The company serves its products to commercial new construction, commercial repair and remodel, residential new construction, and residential repair and remodel (R&R). Its geographical segment is Central, Midwest, New York, Northeast, Southern, Southeast, Southwest, Western and Canada, and Ames. The company generates maximum revenue from Wallboard products.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.